Prevalence of insulin resistance among hypertensive patients undergoing antihypertensive therapy
DOI:
https://doi.org/10.46858/vimshsj.8403Keywords:
Antihypertensive agents, Blood glucose, Hypertension, Insulin resistanceAbstract
Background: Hypertensive patients undergoing antihypertensive therapy are more prone to insulin resistance (IR). Thus, it is essential to monitor its prevalence, metabolic consequences and to individualize antihypertensive therapy to negate its potential adverse effects. Therefore, the presented study assessed the prevalence of IR among hypertensive patients undergoing antihypertensive therapy. Methodology: This prospective study involved 200 patients of either sex, diagnosed with essential hypertension, and undergoing treatment. Data regarding age, gender, medical history, body mass index (BMI), and waist circumference were collected. Laboratory investigations for fasting blood sugar levels, serum fasting Insulin levels, lipid profile, and glycosylated hemoglobin were performed. Homeostatic model assessment of IR (HOMA IR) was calculated. Statistical analysis was performed by using R software (Version. 3.6.0). Results: The prevalence of IR in hypertensive nondiabetic patients was 39%. The mean age and BMI of patients were 58.70 ± 16.64 year and 23.10 ± 2.57 kg/m2, respectively. The mean fasting blood sugar levels were 108.24 ± 20.99 mg/ dl. The mean HOMA IR levels were >2.8. IR was more in users of beta?blockers than in angiotensin?converting enzyme (ACE) inhibitors and calcium channel blockers, as a significant association was observed between the class of hypertensive drugs and presence of IR (P < 0.05). A significant association (P < 0.05) was observed between the duration of hypertension and IR indicated by HOMA IR >2.5 in patients on beta?blockers and on ACE inhibitors. Conclusion: Antihypertensive drugs like beta?blockers decrease insulin sensitivity in hypertensive patients leading to increased prevalence of IR.
Downloads
References
Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006;81:796?806.
Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev 2019;98:2133-223.
Ramalingam L, Menikdiwela K, LeMieux M, Dufour JM, Kaur G, Kalupahana N, et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Biochim Biophys Acta Mol Basis Dis 2017;1863:1106?14.
Xiao WY, Ning N, Tan MH, Jiang XS, Zhou L, Liu L, et al. Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. Hypertens Res 2016;39:321 6.
Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double blind, controlled study of 21 obese hypertensives. Circulation 2000;102:1802 6.
Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135 41.
Salgado AL, Carvalho Ld, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA IR) in the differentiation of patients with non alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol 2010;47:165 9.
Nishimura H, Sanaka T, Tanihata Y, Naito T, Higuchi C, Otsuka K. Losartan elevates the serum high molecular weight adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008;31:1611 8.
Mohteshamzadeh M, Wilkinson R, Thomas SH. Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: Results of a 3 year study. Am J Hypertens 2005;18:452 6.
Garcia Puig J, Ruilope LM, Luque M, Fernandez J, Ortega R, Dal Re R. AVANT Study Group Investigators. Glucose metabolism in patients with essential hypertension. Am J Med 2006;119:318 32.
Mancusi C, de Simone G, Best LG, Wang W, Zhang Y, Roman MJ, et al. Myocardial mechano energetic efficiency and insulin resistance in non diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol 2019;18:56.
Perl S, Schmölzer I, Sourij H, Pressl H, Eder M, Zweiker R, et al. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiol 2010;139:289 96.
Huang GZ, Tang YH, Wang BY, Zhang B, Hu TJ, Zhang L, et al. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J 2011;32:1017 21.
Siegel D, Swislocki AL. Effects of antihypertensives on glucose metabolism. Metab Syndr Relat Disord 2007;5:211?9.
Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: Similarities and differences. J Clin Hypertens (Greenwich) 2011;13:238?43.
Huang Y, Li Y, Liu Q, Zhang J, Zhang Z, Wu T, et al. Telmisartan attenuates obesity induced insulin resistance via suppression of AMPK mediated ER stress. Biochem Biophys Res Commun 2020;523:787 94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Dr. Tejas Rane, Dr. Sanjay T. Thorat, Dr. Akshay R. Kulkarni, Dr. Aniket B. Avhad, Dr. Parikshit Mankar, Dr. Niyati Kaila2 Kaila
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
